Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-01

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients.

The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma

NCT04020705

Glaucoma

COMPLETED NA

OMNI in Open-angle Glaucoma Treatment

NCT04503356

Open Angle Glaucoma Cataract Eye Diseases +1 more

UNKNOWN NA

OCT Angiography in the Glaucoma Diagnosis

NCT04437446

Glaucoma

UNKNOWN NA

The Canadian Glaucoma Study

NCT00262626

Glaucoma

TERMINATED NA

Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution

NCT05315206

Primary Open Angle Glaucoma

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-angle Glaucoma Visual Field

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MEMOPTIC added to the usual treatment of glaucoma

Group Type EXPERIMENTAL

MEMOPTIC

Intervention Type DRUG

Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following

usual treatment of glaucoma

Group Type ACTIVE_COMPARATOR

usual treatment of glaucoma

Intervention Type DRUG

Patients will receive only their usual treatment of glaucoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEMOPTIC

Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following

Intervention Type DRUG

usual treatment of glaucoma

Patients will receive only their usual treatment of glaucoma.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects
* age between 20 and 80 years old
* Well controled intra-ocular pressure under treatment (PIO\<21mmHg or decreased by 20% compared to initial the PIO)

Exclusion Criteria

* retinal or macular disease
* diagnosis of cataract or surgery of cataract during the follow-up
* allergy to citicolin
* ocular hypertonia due to a secondary cause (like corticosteroids)
* history of anterior, intermediate or posterior uveitis
* general treatment affecting PIO (beta blockers, corticosteroids)
* pregnancy or breastfeeding

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No